Analysts foresee more revenue Vertex Pharma

Tomorrow the American Vertex Pharma will report its past quarter's results. Over the current book year the total revenue will be 3,01 billion USD (consensus estimates). This is quite more than 2017's revenue of 2,49 billion USD.

Historical revenues and results Vertex Pharma plus estimates 2018

stock analysis

The analysts expect for 2018 a net profit of 982 million USD. Most of the analysts anticipate on a profit per share of 3,8 USD. With this the price/earnings-ratio is 46,23.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a moderate 1 percent.

Based on the current number of shares Vertex Pharma 's market capitalization equals 43,62 billion USD. The Vertex Pharma stock was the past 12 months quite unstable. Since last October the stock is 14 percent higher. This year the stock price moved between 137 and 195 dollar. Since 2008 the stock price is almost 672 percent higher.

On Friday the stock closed at 175,69 USD.

Historical stock prices Vertex Pharma from 2007 till 2018

stock analysis vertexpharma

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.